Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874465 | 1.00 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL10724223 | 1.00 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL12606502 | 0.96 | PDE8B (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL29496240 | 0.92 | MEN1 (0.40) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL27426143 | 0.88 | HSD17B10 (0.47) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL6921210 | 0.86 | ATM (0.47) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL16551790 | 0.86 | ATM (0.47) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL6350025 | 0.86 | ATM (0.47) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL20410 | 0.86 | SMN1; SMN2 (0.45) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL863388 | 0.86 | SMN1; SMN2 (0.45) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-1613762-B1 | PROCESS FOR PRODUCING ENANTIOPURE BETA-AMINO ACID DERIVATIVES, AND ENANTIOPURE BETA-AMINO ACID DERIVATIVES | SOLVAY (BE) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-7592476-B2 | Process for producing enantiopure β-amino acid derivatives, and enantiopure β-amino acid derivatives | SOLVAY S.A. (BE) | 2009-09-22 | — | — | US | disclosed |
| US-7592476-B2 | Process for producing enantiopure β-amino acid derivatives, and enantiopure β-amino acid derivatives | SOLVAY S.A. (BE) | 2009-09-22 | — | — | US | disclosed |
| US-20060211097-A1 | Process for producing enantiopure beta-amino acid derivatives, and enantiopure beta-amino acid derivatives | SOLVAY S.A. (BE) | 2006-09-21 | — | — | US | disclosed |
| US-4634716-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1987-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | GABRA1 3122/4885GABRG2 3154/4885GABRB3 2786/4885 |
| US-20060211097-A1 | Process for producing enantiopure beta-amino acid derivatives, and enantiopure beta-amino acid derivatives | LPL, CEL, IL4I1 | GABRA1 664/4885GABRG2 726/4885GABRB3 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.